Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

Abstract Background Lung cancer patients with KRAS mutation(s) have a poor prognosis due in part to the development of resistance to currently available therapeutic interventions. Development of a new class of anticancer agents that directly targets KRAS may provide a more attractive option for the...

Full description

Bibliographic Details
Main Authors: Ke Xu, Dongkyoo Park, Andrew T. Magis, Jun Zhang, Wei Zhou, Gabriel L. Sica, Suresh S. Ramalingam, Walter J. Curran, Xingming Deng
Format: Article
Language:English
Published: BMC 2019-04-01
Series:Molecular Cancer
Subjects:
KRAS
Agonist
Apoptosis
Autophagy
NSCLC
Therapy
Online Access:http://link.springer.com/article/10.1186/s12943-019-1012-4

Internet

http://link.springer.com/article/10.1186/s12943-019-1012-4

Similar Items